Novartis (NVS) Enters $1.7 Billion Development Deal, Says Report

We recently published 13 Best ADR Stocks to Invest In.  Novartis AG (NYSE:NVS) is one of the best ADR stocks.

Swiss pharmaceutical giant Novartis AG (NYSE:NVS) has entered into a massive $1.7 billion partnership with British pharmaceutical firm Relation Therapeutics to develop treatments for allergic diseases, according to a report from Bloomberg which surfaced on December 9th. Through this deal, the firm will use Relation’s AI platform to develop new drugs by studying the genetics involved in diseases.

Novartis (NVS) Enters $1.7 Billion Development Deal, Says Report

A day earlier, Novartis AG (NYSE:NVS)’s shares were upgraded to Overweight from Neutral by investment bank JPMorgan. As part of its coverage, the bank also raised the firm’s share price target to CHF125 from an earlier CHF95 as it based its optimism on the back of positive sentiment regarding the firm’s outlook for 2026.nNovartis AG (NYSE:NVS) has been busy with partnerships in 2025 as its deal with Relation isn’t the only one that it has inked. For instance, the firm bought Avidity Biosciences for a whopping $12 billion price tag in October. Through the deal, Novartis AG (NYSE:NVS) aims to boost its RNA drug development portfolio to cover rare ailments such as the Duchenne Muscular Atrophy. Apart from the Avidity deal, the Swiss pharma firm has also entered into agreements to buy Tourmaline Bio for $1.4 billion for its cardiovascular portfolio and Regulus Therapeutics for a $1.7 billion price tag to boost its renal portfolio.

While we acknowledge the risk and potential of NVS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NVS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.